3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1/2
3
Phase 1
2
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia
4
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Thalassemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Leukemia, Prolymphocytic
1
Kidney Transplantation
1
Kidney Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Carcinoma, Renal Cell
1
Interventions
fludarabine phosphate
10
Cyclophosphamide
10
Peripheral Blood Stem Cell Transplantation
9
Cyclosporine
7
Mycophenolic Acid
6
Filgrastim
6
Antilymphocyte Serum
6
Whole-Body Irradiation
5
Busulfan
5
Radiotherapy
4
Psychiatric Rehabilitation
4
Cytarabine
4
Methylprednisolone
3
Methotrexate
3
Melphalan
3
Cord Blood Stem Cell Transplantation
3
Aprepitant
3
thymoglobulin
2
Therapeutics
2
Tacrolimus
2
Polymerase Chain Reaction
2
Ondansetron
2
Mesna
2
Flow Cytometry
2
Dexamethasone
2
Calcium Dobesilate
2
Analgesia
2
sargramostim
1
plerixafor
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Myeloproliferative Disorders
×
Alemtuzumab
×
Clear all
NCT00578539
2016-04-22
REGALE
Baylor College of Medicine
Phase NA
Terminated
24 enrolled
7 charts